modelAldosterone
Extends from Pharmacolibrary.Drugs.ATC.H.H02AA01.
Information
| name: | Aldosterone | |
| ATC code: | H02AA01 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 0.05 | mg |
| volume of distribution: | 0.4 | L |
| clearance: | 7.4 | mL/min/kg |
| other parameters in model implementation | ||
Aldosterone is a mineralocorticoid hormone produced by the adrenal cortex that plays a central role in the regulation of blood pressure, sodium, and potassium balance. It is not used as an approved therapeutic drug clinically; rather, its analogs and antagonists are used in the treatment of conditions like hypertension and heart failure.
Pharmacokinetics
Estimated pharmacokinetic parameters based on limited human data, as clinical PK studies specifically administering exogenous aldosterone in humans are sparse.
References
Suh, A, et al., & Rosa, RM (2004). Racial differences in potassium disposal. Kidney international 66(3) 1076–1081. DOI:10.1111/j.1523-1755.2004.00857.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/15327401
Li, Y, et al., & Yu, Y (2016). Sodium Infusion Test for Diagnosis of Primary Aldosteronism in Chinese Population. The Journal of clinical endocrinology and metabolism 101(1) 89–95. DOI:10.1210/jc.2015-2840 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26565948
Meijers, WC, et al., & de Boer, RA (2014). Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis. Journal of the American Heart Association 3(5) e000962–None. DOI:10.1161/JAHA.114.000962 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25237044
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)